Abstract

BackgroundInterim treatment outcomes at 6-months for multidrug-resistant tuberculosis (MDR-TB) treatment are among the most basic performance monitoring and key evaluation indicators in the Stop and End TB strategy of the World Health Organization (WHO). Therefore, this study was conducted to evaluate the interim treatment outcomes of MDR-TB patients in Pakistan.MethodsThis study was conducted at the Programmatic Management Unit for Drug-resistance TB (PMDT) site of the National Tuberculosis Program (NTP), Pakistan. It is located in the Chest Disease Unit (CDU) of the Bahawal Victoria Hospital (BVH), Bahawalpur, Punjab, Pakistan. Data was collected between April 1, 2014 and December 31, 2015. The medical records, Electronic Nominal Recording Reporting System (ENRS) data and MRD-TB notification forms of the MDR-TB patients registered at the PMDT site were reviewed to obtain data. For reporting and calculation of interim treatment outcomes, standardized WHO methodology was adopted. Simple logistic regression analysis was used to examine the possible association between the dependent variable (i.e. unsuccessful interim treatment outcome) and selected socio-demographic and clinical variables.ResultsA total of 100 drug-resistant TB (DR-TB) patients (all types) were registered during the study period. Out of these, 80 were MDR-TB patients for whom interim results were available. Out of the 80 MDR-TB cases, 48 (60%) were classified under the successful interim treatment outcome category. The remaining 40% had unsuccessful 6-month treatment outcomes and 12 (15%) patients died, while nine (11.3%) were lost to follow-up by six months. The final predictors of unsuccessful interim treatment outcomes were; being resistant to ofloxacin (AOR 3.23, 95% CI 0.96–10.89; p-value = 0.04), having above normal baseline serum creatinine levels (AOR 6.49, 95% CI 1.39–30.27; p-value = 0.02), and being culture positive at the second month of treatment (AOR 6.94, 95% CI 2–24.12; p-value = 0.01).ConclusionsDespite free treatment and programmatic efforts to ensure patient adherence, the high rate of unsuccessful interim treatment outcomes is concerning. The identified risk factors for unsuccessful interim treatment outcomes in the current study provides clinicians an opportunity to identify high-risk patients and ensure enhanced clinical management and greater treatment success rates.

Highlights

  • Interim treatment outcomes at 6-months for multidrug-resistant tuberculosis (MDR-TB) treatment are among the most basic performance monitoring and key evaluation indicators in the Stop and End TB strategy of the World Health Organization (WHO)

  • A major obstacle in the successful control of tuberculosis (TB) is multidrug-resistant TB (MDR-TB), defined as mycobacterium strains resistant to both isoniazid and rifampicin

  • During the course of treatment the National Tuberculosis Programme (NTP) managers and healthcare authorities/ providers require an indication of the treatment effectiveness among the enrolled patients [6]

Read more

Summary

Introduction

Interim treatment outcomes at 6-months for multidrug-resistant tuberculosis (MDR-TB) treatment are among the most basic performance monitoring and key evaluation indicators in the Stop and End TB strategy of the World Health Organization (WHO). During the course of treatment the National Tuberculosis Programme (NTP) managers and healthcare authorities/ providers require an indication of the treatment effectiveness among the enrolled patients [6]. Sputum culture negativity during the early months of MDR-TB treatment is widely used as a reliable interim indicator of non-infectiousness (i.e. microbiological endpoint) and for tracking clinical progress and the effectiveness of treatment [7, 8]. Sputum culture conversion at two months of treatment has been reported as a predictor of successful treatment outcomes among MDR-TB patients [10]. A recently conducted study which included 1712 MDR-TB patients from two separate cohorts, found statistically significant positive associations between sputum culture conversion at two months of treatment and successful outcomes among patients with unknown HIV status. Figures on loss to follow-up at six months due to a variety of reasons such as: symptoms relief, adverse drug reactions, patient’s lack of awareness about the total treatment duration [12] is helpful in the assessment of adherence to treatment regimens, and overall performance of the programme [6] (refer to Additional file 1: Appendix S1 section for study schema)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call